Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Transition Care for Young People with Rare Bone and Mineral Conditions: A Scoping Review.

Advances in therapy·2026
Same author

Transition Care for Young People with Rare Bone and Mineral Conditions: A Scoping Review.

Advances in therapy·2026
Same author

Endocrine-related osteoporosis: the state of the art.

Frontiers in endocrinology·2026
Same author

Clinical decision-making in rare bone diseases - A survey among members of the European Paediatric Orthopaedic Society (EPOS) and the European Reference Network on Rare Bone Diseases (ERN BOND).

Journal of children's orthopaedics·2026
Same author

Intra-fraction errors and inter-fraction deformation during pancreas SBRT: Analysis and predictability of dose variations for upper gastrointestinal organs.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Clinical features of Italian adult individuals with X-linked hypophosphatemia: a multicenter retrospective study.

Endocrine connections·2026

Related Experiment Video

Updated: May 23, 2026

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis
02:08

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis

Published on: July 5, 2024

Thiazolidinediones and bone.

Alberto Falchetti1, Laura Masi, Maria Luisa Brandia

  • 1Department of Internal Medicine, University of Florence Centro di Riferimento Regionale sui Tumori Endocrini Ereditari Azienda Ospedaliero-Universitaria Careggi, Florence, Italy a DeGene Spin-off, University of Florence, Florence, Italy.

Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
|March 31, 2012
PubMed
Summary
This summary is machine-generated.

Thiazolidinediones (TZDs), used for type 2 diabetes, may increase osteoporosis and fracture risk in older adults by affecting bone formation. Healthcare providers should assess patients for osteoporosis risk before prescribing TZDs.

More Related Videos

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Related Experiment Videos

Last Updated: May 23, 2026

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis
02:08

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis

Published on: July 5, 2024

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Area of Science:

  • Endocrinology
  • Geriatrics
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus and osteoporosis are common, multifactorial conditions in aging populations.
  • Patients with type 2 diabetes have increased fracture risk, often linked to falls, despite potentially higher bone mineral density.
  • Thiazolidinediones (TZDs) are widely used to improve insulin sensitivity in type 2 diabetes.

Purpose of the Study:

  • To investigate the impact of thiazolidinediones (TZDs) on bone health in patients with type 2 diabetes.
  • To examine the relationship between TZD use, bone mineral density, and fracture risk in older adults.
  • To inform clinical practice regarding TZD prescription in diabetic patients with osteoporosis risk factors.

Main Methods:

  • Review of clinical data correlating thiazolidinedione (TZD) intake with bone mineral density (BMD) and fracture incidence.
  • Analysis of the mechanism of action of TZDs involving peroxisome proliferator-activated receptor-gamma (PPAR-γ) activation.
  • Evaluation of TZD effects on adipogenesis and osteoblastogenesis pathways.

Main Results:

  • Thiazolidinedione (TZD) use in older type 2 diabetes patients correlates with decreased bone mineral density (BMD) at the femoral neck and hip.
  • TZD treatment is associated with an increased risk of fractures in this patient population.
  • TZD activation of PPAR-γ may lead to increased bone marrow adiposity and reduced osteoblastogenesis, impairing bone formation.

Conclusions:

  • Thiazolidinediones (TZDs) may negatively impact bone health, increasing osteoporosis and fracture risk in older adults with type 2 diabetes.
  • Healthcare providers must carefully evaluate osteoporosis risk factors before initiating TZD therapy.
  • Regular clinical follow-up is crucial for patients with type 2 diabetes treated with thiazolidinediones (TZDs).